{"id":49108,"date":"2022-10-03T22:02:17","date_gmt":"2022-10-03T20:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/"},"modified":"2022-10-03T22:02:17","modified_gmt":"2022-10-03T20:02:17","slug":"kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/","title":{"rendered":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis"},"content":{"rendered":"
\n

\nCompany to host a virtual Research and Development Day during the fourth quarter 2022<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis (AIH).\n<\/p>\n

<\/a><\/p>\n

\nAIH is a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients\u2019 physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 140,000 individuals, with incidence rates increasing. The cause of this condition remains unclear. Females are affected four times as often as males. Standard of care treatment for AIH is immunosuppressive treatment with chronic corticosteroids that can lead to additional morbidity and mortality. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression using corticosteroids.\n<\/p>\n

\nThe PORTOLA trial (KZR-616-208) is a randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating the safety and efficacy of zetomipzomib in patients with AIH that are insufficiently responding to standard of care or have relapsed. The target enrollment will be 24 patients, who will be randomly assigned (2:1) to receive either zetomipzomib with prednisone or placebo with prednisone for 24 weeks, with a protocol-directed steroid taper by Week 14. The primary efficacy endpoint will measure the proportion of patients who achieve a complete response measured as normalization of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels with a successful corticosteroid taper by Week 24.\n<\/p>\n

\n\u201cZetomipzomib is a unique small molecule with the potential to be a non-immunosuppressive, anti-inflammatory treatment for multiple autoimmune diseases. We plan to run PORTOLA, an early proof-of-concept study in parallel to our other development efforts, including a late-phase efficacy trial for patients with lupus nephritis and a potential program in patients with systemic lupus erythematosus,\u201d said Noreen R. Henig, M.D., Kezar\u2019s Chief Medical Officer. \u201cAutoimmune hepatitis is a disease where there is a good fit between the pathophysiology of the disease and mechanism of action of zetomipzomib, as well as significant unmet medical need and few alternative therapies. We are grateful to the Autoimmune Hepatitis Association for their support of the patients and families with AIH and their connection to dedicated physicians and researchers in autoimmune liver disease.\u201d\n<\/p>\n

\n\u201cPatients with autoimmune hepatitis need new therapies that can better treat their disease. Lifelong maintenance therapy is required for most patients with AIH and an alternative regimen that reduces or removes the need for immunosuppression with corticosteroids would be welcomed by patients and the medical community,\u201d commented Craig Lammert, M.D., Assistant Professor of Medicine at Indiana University and Executive Director of the Autoimmune Hepatitis Association.\n<\/p>\n

\nAbout Zetomipzomib (KZR-616)<\/b>\n<\/p>\n

\nZetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.\n<\/p>\n

\nAbout Autoimmune Hepatitis<\/b>\n<\/p>\n

\nAutoimmune Hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients\u2019 physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 140,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression using corticosteroids.\n<\/p>\n

\nAbout Kezar Life Sciences<\/b>\n<\/p>\n

\nKezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company\u2019s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com<\/a>.\n<\/p>\n

\nCautionary Note on Forward-looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cbelieve\u201d, \u201cplan\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar\u2019s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the design, progress, timing, scope and results of clinical trials, the anticipated regulatory development and future clinical trials involving Kezar\u2019s product candidates, the likelihood that data will support future development and therapeutic potential, the association of data with treatment outcomes and the likelihood of obtaining regulatory approval of Kezar\u2019s product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, changes in expected or existing competition, the uncertainties and timing of the regulatory approval process and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar\u2019s filings with the U.S. Securities and Exchange Commission, including the \u201cRisk Factors\u201d contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Gitanjali Jain
\n
Vice President, Investor Relations and External Affairs
\n
gjain@kezarbio.com<\/a><\/p>\n

Media Contact:<\/b>
Julia Deutsch
\n
Solebury Strategic Communications
\n
jdeutsch@soleburystrat.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host a virtual Research and Development Day during the fourth quarter 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49108","6":"format-standard","7":"category-industry"},"yoast_head":"\nKezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company to host a virtual Research and Development Day during the fourth quarter 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T20:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis\",\"datePublished\":\"2022-10-03T20:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/\"},\"wordCount\":1147,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003006001\\\/en\\\/1590458\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/\",\"name\":\"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003006001\\\/en\\\/1590458\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"datePublished\":\"2022-10-03T20:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003006001\\\/en\\\/1590458\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003006001\\\/en\\\/1590458\\\/21\\\/Kezar_Life_Sciences_logo_July_2022.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend","og_description":"Company to host a virtual Research and Development Day during the fourth quarter 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-03T20:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis","datePublished":"2022-10-03T20:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/"},"wordCount":1147,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/","url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/","name":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","datePublished":"2022-10-03T20:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221003006001\/en\/1590458\/21\/Kezar_Life_Sciences_logo_July_2022.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-receives-fda-clearance-of-ind-for-zetomipzomib-for-the-treatment-of-autoimmune-hepatitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49108"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49108\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}